CorMedix Inc. (CRMD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• CorMedix (CRMD) Q1 2026: Full-Year Revenue Guidance Raised by $25M as DefenCath Demand Outpaces Reimbursement Transition
  May 14, 2026
• CoreMedix (CRMD) Q4 2025: Malenta Acquisition Adds $37M, DefendCast Faces Price Reset in 2026
  March 05, 2026
• CoreMedix (CRMD) Q3 2025: Melinta Acquisition Adds $15.5M Revenue, Shifts Growth Profile
  November 12, 2025
• Core Medics (CRMD) Q2 2025: Malinta Deal Adds $125M Revenue, Unlocking Specialty Pharma Scale
  August 07, 2025
• CoreMedix (CRMD) Q1 2025: R&D Spend Jumps 281% as DefendCath Uptake Expands
  July 06, 2025

Browse all companies